Cereno Scientific signs agreement with University of Michigan to bring new preclinical candidate CS585 into clinical phase
Cereno Scientific today announced that a collaboration agreement for the full preclinical development program of the new drug candidate CS585 has been signed with the University of Michigan. The development agreement includes the successful transition of CS585 to a clinical Phase I program. The IND-enabling work will be conducted at the University of Michigan, a top-ranked public research university in the US with an extensive track record of successful collaborations with industry. CS585 is in development within cardiovascular diseases.
“The preclinical development with CS585 will start immediately under the lead of Dr Michael Holinstat. We are glad to be working together with a research team of this caliber and anticipate a positive journey ahead for both CS585 and Cereno,” says Sten R. Sörensen, CEO at Cereno Scientific.
Preclinical drug candidate CS585 is a small molecule, an analog to the endogenous metabolite 12-HETrE. It is a stable, selective, and potent IP (prostacyclin) receptor agonist that has demonstrated potential to significantly advance treatments within selected cardiovascular diseases in initial in vivo animal models.
”My research team and I look forward to continue into a preclinical development program for CS585 together with Cereno. The drug candidate has already provided promising data,” says Dr Michael Holinstat PhD, FAHA, Department of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery at University of Michigan Medical School.
The University of Michigan is a top-ranked public research university with one of the largest annual collegiate research budgets of any university in the US. Over $1.6 billion is spent on research and development annually across its 2.8 million square feet of laboratory space. The university has 6,200 faculty members and roughly 38,000 employees.
In March, Cereno announced that this preclinical drug candidate was obtained through an option agreement with University of Michigan which provides Cereno with the exclusive rights to evaluate its market potential. If the evaluation in the preclinical development program is successful, Cereno can exercise its option to exclusively in-license the drug for further clinical development and commercialization. Cereno will share more details about the CS585 preclinical program as it develops over the coming 24 months.
For further information, please contact:
Daniel Brodén, CFO
Tel: +46 768 66 77 87
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.